Table 6.
Top 10 co-cited references involved in the research of RCC immunotherapy.
| Title | First author | Year | Citations | Journals | IF (2020) |
|---|---|---|---|---|---|
| Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | Robert J Motzer | 2015 | 615 | New England Journal of Medicine | 91.245 |
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Robert J Motzer | 2007 | 461 | New England Journal of Medicine | 91.245 |
| Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma | Robert J Motzer | 2018 | 400 | New England Journal of Medicine | 91.245 |
| Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma | Gary Hudes | 2007 | 354 | New England Journal of Medicine | 91.245 |
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Suzanne L Topalian | 2012 | 340 | New England Journal of Medicine | 91.245 |
| Sorafenib in advanced clear-cell renal-cell carcinoma | Bernard Escudier | 2007 | 332 | New England Journal of Medicine | 91.245 |
| Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy | G Fyfe | 1995 | 310 | Journal of Clinical Oncology | 44.54 |
| Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | Brian I Rini | 2019 | 298 | New England Journal of Medicine | 91.245 |
| Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer | R C Flanigan | 2001 | 282 | New England Journal of Medicine | 91.245 |
| Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial | G H Mickisch | 2001 | 260 | Lancet | 79.321 |
IF, impact factor.